Marshall Financial Group LLC Sells 11,935 Shares of Abbott Laboratories $ABT

Marshall Financial Group LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 78.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,198 shares of the healthcare product maker’s stock after selling 11,935 shares during the period. Marshall Financial Group LLC’s holdings in Abbott Laboratories were worth $401,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in ABT. Tompkins Financial Corp grew its position in shares of Abbott Laboratories by 0.5% during the 4th quarter. Tompkins Financial Corp now owns 103,131 shares of the healthcare product maker’s stock worth $12,921,000 after buying an additional 532 shares during the period. Gradient Investments LLC raised its position in shares of Abbott Laboratories by 15.7% in the 4th quarter. Gradient Investments LLC now owns 346,541 shares of the healthcare product maker’s stock valued at $43,418,000 after acquiring an additional 47,135 shares during the period. Regent Peak Wealth Advisors LLC raised its position in shares of Abbott Laboratories by 4.4% in the 4th quarter. Regent Peak Wealth Advisors LLC now owns 5,393 shares of the healthcare product maker’s stock valued at $676,000 after acquiring an additional 226 shares during the period. Armstrong Advisory Group Inc. boosted its stake in Abbott Laboratories by 12.4% during the 4th quarter. Armstrong Advisory Group Inc. now owns 4,389 shares of the healthcare product maker’s stock worth $550,000 after acquiring an additional 483 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Abbott Laboratories by 9.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 1,545,958 shares of the healthcare product maker’s stock valued at $197,622,000 after purchasing an additional 134,139 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABT. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Oppenheimer decreased their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Barclays reduced their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Finally, Raymond James Financial decreased their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Stock Down 0.6%

Abbott Laboratories stock opened at $104.87 on Tuesday. The company has a 50 day moving average of $112.36 and a 200-day moving average of $122.77. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a twelve month low of $104.10 and a twelve month high of $139.06. The stock has a market capitalization of $182.65 billion, a PE ratio of 28.19, a price-to-earnings-growth ratio of 1.68 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.